Huntington National Bank lowered its position in shares of GRIFOLS S A/S (NASDAQ:GRFS) by 43.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,810 shares of the biotechnology company’s stock after selling 1,388 shares during the period. Huntington National Bank’s holdings in GRIFOLS S A/S were worth $36,000 at the end of the most recent reporting period.
Other hedge funds have also recently modified their holdings of the company. Advisors Asset Management Inc. lifted its stake in GRIFOLS S A/S by 58.0% during the fourth quarter. Advisors Asset Management Inc. now owns 3,629 shares of the biotechnology company’s stock worth $67,000 after purchasing an additional 1,332 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its stake in GRIFOLS S A/S by 45.3% during the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 5,770 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 1,799 shares during the last quarter. SG Americas Securities LLC bought a new stake in GRIFOLS S A/S during the fourth quarter worth about $144,000. Amundi Pioneer Asset Management Inc. bought a new stake in GRIFOLS S A/S during the fourth quarter worth about $242,000. Finally, Quadrant Capital Group LLC lifted its stake in GRIFOLS S A/S by 20.2% during the fourth quarter. Quadrant Capital Group LLC now owns 14,098 shares of the biotechnology company’s stock worth $252,000 after purchasing an additional 2,365 shares during the last quarter. 19.96% of the stock is owned by hedge funds and other institutional investors.
NASDAQ GRFS opened at $18.85 on Thursday. GRIFOLS S A/S has a 1-year low of $17.42 and a 1-year high of $24.97. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.77 and a quick ratio of 1.22. The stock has a market capitalization of $13.39 billion, a PE ratio of 16.11, a P/E/G ratio of 1.39 and a beta of 1.07.
Several brokerages have issued reports on GRFS. Zacks Investment Research lowered GRIFOLS S A/S from a “hold” rating to a “sell” rating in a research note on Monday, April 1st. BidaskClub lowered GRIFOLS S A/S from a “sell” rating to a “strong sell” rating in a research note on Tuesday. Berenberg Bank lowered GRIFOLS S A/S from a “buy” rating to a “hold” rating in a research note on Friday, February 8th. Finally, Morgan Stanley dropped their price target on GRIFOLS S A/S from $20.00 to $19.00 and set an “underweight” rating for the company in a research note on Wednesday, January 2nd. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $21.00.
ILLEGAL ACTIVITY NOTICE: “GRIFOLS S A/S (GRFS) Shares Sold by Huntington National Bank” was originally published by WKRB News and is the sole property of of WKRB News. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.wkrb13.com/2019/04/18/grifols-s-a-s-grfs-shares-sold-by-huntington-national-bank.html.
GRIFOLS S A/S Profile
Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.
Featured Story: Analyzing a company’s cash flow statement
Want to see what other hedge funds are holding GRFS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GRIFOLS S A/S (NASDAQ:GRFS).
Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.